LP-300 Demonstrates 8.3-Month Median PFS in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

“The patients participating in HARMONIC™ are facing a serious illness with real courage, and often with few remaining options. Their willingness to take part in this research is what makes progress possible, and it is the reason we approach this work with both urgency and humility. The emerging data in patients with the EGFR L858R mutation — an 8.3-month progression-free survival signal in a post-TKI setting, without additional toxicity burden — is an encouraging early finding. We understand that this is preliminary data in a small patient cohort, but the signal is consistent with the biology, and it warrants a focused, disciplined development path. Our Type C meeting with the FDA is a collaborative step in that direction. We want their input, we respect their process, and our goal is straightforward — to determine whether LP-300 can make a meaningful difference for patients who are running out of options, and to get there as efficiently as we can.”, said Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.